Answers are grounded in this paper and cite their sources.
Introduction: While uncommon, submacular hemorrhage (SMH) is caused by many etiologies and can result in severe vision loss, especially if untreated. Currently there are no accepted guidelines for the treatment of SMH. The current literature was reviewed to provide a better understanding and analyze results of the current treatments for the most common etiologies of SMH.Areas covered: The authors researched human/animal studies related to SMH treatment, articles describing etiologies of SMH and review articles of the entire subject to compose this manuscript. Literature search was conducted through pubmed using keywords submacular hemorrhage and the corresponding treatments.Expert commentary: Treating SMH using the most common techniques can result in varying outcomes. In office pneumatic displacement may be convenient however it may not completely displace the hemorrhage. Vitrectomy with tissue plasminogen activator and air-fluid exchange is a more aggressive approach and often results in near complete displacement, however VA may not improve due to macular scarring. Anti-VEGF monotherapy, or the combination of anti-VEGF with vitrectomy and pneumatic displacement, has resulted in very good visual outcomes for patients with SMH associated with choroidal neovascularization. Additional studies are needed to determine the most effective treatment.
No takes yet. Share an insight, caveat, or question.
Stroman et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: